CNS Pharmaceuticals

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals' recent submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin, as well as the Company's plans to commence Phase 2 trials during the first quarter of 2021.

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy

HOUSTON, Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the...

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

HOUSTON, Sept.  24, 2020  (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group (“IAG”) as the image partner for its upcoming Berubicin clinical trials.

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals to Present at the H.C. Wainwright & Co.

Houston, Texas, Sept.  03, 2020  (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials.

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

HOUSTON, Aug. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

HOUSTON, Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials

HOUSTON, July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today recognizes.

CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day

HOUSTON, July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced today it has...

CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers

HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announces it has entered...

CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has...

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on...

CNS Provides Update on Development Agreement for WP1122

Moleculin Biotech

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company.

UPDATE: Moleculin Biotech, CNS Pharma     shares remain halted on Nasdaq

HOUSTON, May 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that...

CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP1122 and its effect on COVID-19.

UPDATE: Moleculin Biotech and CNS Pharma comment on SEC trading halt

CNS Pharmaceuticals (NASDAQ: CNSP) shares are trading higher on Monday. The company announced that independent research from the University of Frankfurt showed that an active compound in WP1122 completely prevented coronavirus replication in vitro.

Why CNS Pharmaceuticals Is Trading Higher Today

Nano-cap biotech CNS Pharmaceuticals Inc (NASDAQ: CNSP), which develops treatments for cancers of the brain and central nervous systems, said Monday that it has struck an agreement with Canada's WPD Pharma for the development of preclinical drug candidates.

CNS Pharma To Pay Canada's WPD Pharma Up To $1M For Antiviral Drug Development

CNS Pharmaceuticals, Inc. (CNSP) Management on Q4 2019 Results - Earnings Call Transcript

News for CNS Pharmaceuticals Stock (CNSP)